Aftalen muliggør den første markedslancering i Latinamerika for Bavarian Nordics chikungunya‑vaccineRummer mulighed for udvidelse til at dække resten af Latinamerika KØBENHAVN, Danmark, 23. januar 2026 – Bavarian Nordic offentliggjorde i dag en aftale med Eurofarma, som giver dem eksklusive rettigheder til at sælge og distribuere Bavarian Nordics chikungunya‑vaccine, CHIKV VLP, i Brasilien. Eurofarma får desuden forkøbsret til enhver fremtidig mulighed for at registrere og kommercialisere chikungunya‑vaccin ...

Core Insights - Bavarian Nordic A/S has entered into an agreement with Eurofarma for exclusive rights to sell and distribute its chikungunya vaccine, CHIKV VLP, in Brazil, with potential expansion to the rest of Latin America [1][8] - The agreement is based on transfer price and royalty, with Eurofarma responsible for regulatory approval and distribution costs, while Bavarian Nordic will manufacture the vaccine [2][5] - Regulatory submission to the Brazilian Health Regulatory Agency, Anvisa, is anticipated in the first half of 2026, aiming for a vaccine launch in Brazil by the second half of 2027 [3][4] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines, and has a strong portfolio of travel vaccines [9] - Eurofarma, founded in 1972, is a leading Brazilian pharmaceutical company with operations in 24 countries and a significant presence in Latin America, having produced 600 million units in 2024 and achieving net revenue exceeding USD 1.78 billion [10] Vaccine Details - CHIKV VLP is a single-dose, prefilled, adjuvanted VLP recombinant protein vaccine designed for individuals aged 12 and older, with protective immunity developing as early as one week post-vaccination [5][6] - The vaccine is non-infectious, containing no viral genetic material, making it safe for a broad range of individuals [6] Disease Context - Chikungunya is a mosquito-borne disease that has emerged in over 110 countries, with Brazil accounting for more than half of the nearly 500,000 reported cases and over 200 deaths worldwide in 2025 [7] - The disease often presents with severe symptoms, and a significant percentage of patients may develop chronic symptoms lasting months or years [7]

Core Viewpoint - Bavarian Nordic A/S has received acceptance from Health Canada for the review of its chikungunya vaccine candidate, CHIKV VLP, which aims to prevent chikungunya virus infection in individuals aged 12 and older, with potential approval expected in the first half of 2026 [1][3]. Group 1: Vaccine Development and Approval - The New Drug Submission for CHIKV VLP is based on data supporting recent approvals in the US, EU, and UK, including results from two phase 3 clinical trials involving over 3,500 participants aged 12 and older [2][4]. - The vaccine demonstrated a neutralizing antibody response in up to 97.8% of vaccinated individuals 21 days post-vaccination, with a seroresponse rate of 96.8% at day 15 for the 12-64 age group and 82.3% for those over 65 [2]. - CHIKV VLP is designed to be non-infectious, containing no viral genetic material, making it suitable for a broad population [4]. Group 2: Market Context and Disease Impact - Chikungunya is a mosquito-borne disease that has emerged in over 110 countries, causing significant outbreaks, particularly in popular travel destinations [5]. - In 2024, there were 620,000 reported cases of chikungunya globally, with over 200 deaths, indicating a substantial public health concern [5]. - The disease often presents with severe symptoms, including incapacitating joint pain, and a significant percentage of patients may develop chronic arthritis [5]. Group 3: Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, with a strong portfolio in travel vaccines and public health preparedness [6].